AbbVie: Psoriasis trials

The registry lists 74 Psoriasis studies with AbbVie as lead sponsor. 0 are open to participants now and 41 have results posted.

Phase 1 7Phase 2 5Phase 3 29Phase 4 4No phase 30(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp PsoriasisCompletedNCT05969223Phase 4Results posted
• A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe PsoriasisTerminatedNCT05044234Phase 2Results posted
• Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic TherapyCompletedNCT04908475Phase 4Results posted
• Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar InvolvementCompletedNCT04713592Phase 3Results posted
• A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease SymptomsCompletedNCT04435600Phase 3Results posted
• A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or IxekizumabCompletedNCT04102007Phase 3Results posted
• A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque PsoriasisCompletedNCT03875508Phase 3Results posted
• A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque PsoriasisCompletedNCT03875482Phase 3Results posted
• Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque PsoriasisCompletedNCT03478787Phase 3Results posted
• A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic TherapyCompletedNCT03255382Phase 3Results posted
• A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)CompletedNCT03104400Phase 3Results posted
• A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic DrugCompletedNCT03104374Phase 3Results posted
• A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )CompletedNCT03047395Phase 3Results posted
• A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic PsoriasisCompletedNCT03022045Phase 3Results posted
• BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT03000075Phase 2Results posted
• Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE)CompletedNCT02750800Results posted
• BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT02694523Phase 3Results posted
• BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT02684370Phase 3Results posted
• BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT02684357Phase 3Results posted
• BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatmentCompletedNCT02672852Phase 3Results posted
• Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)CompletedNCT02533375Phase 3Results posted
• An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Patients With Immune-Mediated InflammaTorY Diseases (VITALITY)CompletedNCT02451839Results posted
• Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT02203851Phase 2Results posted
• Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR StudyCompletedNCT02196701Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail PsoriasisCompletedNCT02016482Phase 3Results posted
• Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical PracticeCompletedNCT01768858Results posted
• Safety and Efficacy Study of Adalimumab in the Treatment of Plaque PsoriasisCompletedNCT01646073Phase 3Results posted
• An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian FederationCompletedNCT01644396Phase 4Results posted
• Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbiditiesCompletedNCT01401452Results posted
• Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in PsoriasisCompletedNCT01387815Results posted
• Quality of Life and Psychosocial Factors Associated With Severe Psoriasis Following Treatment With AdalimumabCompletedNCT01328366Results posted
• Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab TreatmentCompletedNCT01316224Results posted
• Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque PsoriasisCompletedNCT01265823Phase 4Results posted
• A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. MethotrexateCompletedNCT01251614Phase 3Results posted
• Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affection in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical PracticeCompletedNCT01202565Results posted
• Evaluation of Humira Retention Rate in Psoriasis Patients in Daily Practice and Assessment of Work Productivity and Quality of LifeCompletedNCT01169987Results posted
• Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab TherapyTerminatedNCT01156532Results posted
• Special Investigation in Patients With Psoriasis Vulgaris and Psoriatic Arthritis (All Patients Investigation)CompletedNCT01155570Results posted
• Surveillance of Humira Injection in Korean PatientsCompletedNCT01083121Results posted
• Greek Study of the Quality of Life in Patients With Psoriasis Treated With AdalimumabCompletedNCT01077128Results posted
• Study of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS) in Spain (PROMISE)CompletedNCT01076192Results posted
• A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 InjectionsActive, not recruitingNCT07232004Phase 1
• Study to Evaluate the Effectiveness of Risankizumab in Participants With a Recent Diagnosis of Moderate Plaque Psoriasis in a Real-life Setting in GreeceActive, not recruitingNCT06247319
• An Observational Study to Validate the Cumulative Life Course Impairment (CLCI) Instrument (DermCLCI-p) in Adult Participants With Moderate to Severe Chronic Plaque Psoriasis (PsO)CompletedNCT05959070
• Effect of Long-term Psoriasis on Patients' Life - CORONATECompletedNCT05555953
• Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977Active, not recruitingNCT04862286Phase 3
• Study to Assess the Change in Disease State When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in TaiwanCompletedNCT04818385
• Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World SettingWithdrawnNCT04799990
• Study to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Psoriasis Treated With Subcutaneous Risankizumab Injection According to Standard of CareActive, not recruitingNCT04780516
• Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar PustulosisCompletedNCT04451720Phase 3
• Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic ArthritisCompletedNCT04433442
• Post-Marketing Surveillance Study of Adalimumab in Pediatric Chronic Severe Plaque Psoriasis Patients in KoreaCompletedNCT03925441
• A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Participants With Chronic Plaque PsoriasisCompletedNCT03922607Phase 1
• An Ascending Multiple Dose Study With VTP-43742 in Healthy VolunteersCompletedNCT03724292Phase 1
• Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian FederationCompletedNCT03518047Phase 3
• Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory DiseasesCompletedNCT03339089
• A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in ChinaCompletedNCT03236870
• Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health ServiceCompletedNCT03223012
• A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque PsoriasisCompletedNCT03219437Phase 3
• A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With PsoriasisTerminatedNCT03145948Phase 1
• Real-World Outcome of Psoriasis Subjects in Korea on AdalimumabCompletedNCT03099083
• This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic ArthritisCompletedNCT02772601Phase 1
• A Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate, Adherence to and Utilization Patterns of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in GreeceCompletedNCT02713295
• An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers and Psoriatic PatientsCompletedNCT02555709Phase 1/2
• Post Marketing Observational Study on Venezuelan Patients With PsoriasisWithdrawnNCT01758705
• Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe PsoriasisCompletedNCT01577550Phase 1
• Documentation of Humira in Psoriasis Patients in Routine Clinical PracticeCompletedNCT01077232
• Chronic Plaque Psoriasis (Ps) RegistryCompletedNCT00799877
• Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT00710580Phase 3
• Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT00691964Phase 3
• A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque PsoriasisCompletedNCT00679731Phase 3
• Open Label Continuation Study in Moderate to Severe PsoriasisCompletedNCT00626002Phase 3
• A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT00570986Phase 3
• Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT00292396Phase 2